Are 5‐HT3antagonists effective in obsessive–compulsive disorder? A systematic review of literature
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Objective: The purpose of this literature database search‐based review was to critically consider and evaluate the findings of literature focusing on efficacy and safety of 5‐HT 3 antagonists in the treatment of obsessive–compulsive disorder (OCD), so as to test whether preclinical data match clinical therapeutic trials. Design: The PubMed database has been searched for papers on 5‐HT 3 antagonists and OCD in humans and for animal models of OCD and 5‐HT 3 receptors. Results: Of the clinically tested 5‐HT 3 receptor antagonists, ondansetron has been used to treat OCD in five therapeutic studies, whereas granisetron only in one recent trial. Both showed some efficacy in open studies and superiority to placebo in double‐blind studies, along with fair safety. No animal OCD model directly implicated 5‐HT 3 receptors. Conclusions: Overall, results indicate some utility, but the available literature is too scanty to allow for valid conclusions to be drawn. The mismatch between animal models of obsessive–compulsive disorder and clinical data with 5‐HT 3 antagonists needs more clinical data to ensure that it is not an artefact. Copyright © 2015 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771 · cited 1×
“Obsessive–compulsive disorder (OCD) is severely disabling, with a 2–3% lifetime prevalence in the general population (Ruscio et al., 2010).”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Clomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Leckman, J. F., Denys, D., Simpson, H. B., Mataix-Cols, D., Hollander, E., Saxena, S., Miguel, E. C., Rauch, S. L., Goodman, W. K., Phillips, K. A., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20669 · Cited by 411 · cited 1×
“, 2010) or proposed specifiers (Leckman et al., 2010).”
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 1×
“This could be reflected in an increased glutamate wasting in the cerebrospinal fluid of OCD patients (Chakrabarty et al., 2005).”
BackgroundShould OCD be classified as an anxiety disorder in DSM-V?
Stein, D. J., Fineberg, N. A., Bienvenu, O. J., Denys, D., Lochner, C., Nestadt, G., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2010) · Depression and Anxiety · doi:10.1002/da.20699 · Cited by 212
Functional neuroimaging in obsessive-compulsive disorder
Del Casale, A., Kotzalidis, G. D., Rapinesi, C., Serata, D., Ambrosi, E., Simonetti, A., Pompili, M., Ferracuti, S., Tatarelli, R., & Girardi, P. (2011) · Neuropsychobiology · doi:10.1159/000325223 · Cited by 210
Self-citationMechanisms of action of current and potential pharmacotherapies of obsessive–compulsive disorder
El Mansari, M., & Blier, P. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.005 · Cited by 142
du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.001 · Cited by 133
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122 · cited 1×
“There is evidence for short-term but not long-term (Fineberg et al., 2013) efficacy of higher doses than those used for depressive and other anxiety disorders of clomipramine and selective serotonin (5-HT) reuptake inhibitor (SSRI) antidepressants (ADs) (Rabinowitz et al.”
BackgroundPharmacotherapy for obsessive‐compulsive disorder
Dougherty, D. D., Rauch, S. L., & Jenike, M. A. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20083 · Cited by 83
Differences in Neuropsychological Performance Between Subtypes of Obsessive–Compulsive Disorder
Nedeljkovic, M., Kyrios, M., Moulding, R., Doron, G., Wainwright, K., Pantelis, C., Purcell, R., & Maruff, P. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802653273 · Cited by 67
Toren, P., Weizman, A., Ratner, S., Cohen, D., & Laor, N. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0413 · Cited by 60
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48 · cited 5×
“, 2010), ondansetron and fluvoxamine (Heidari et al., 2014) and granisetron and fluvoxamine (Askari et al.”
BackgroundMethodResultInfluentialPallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.003 · Cited by 42
Cited by
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Clinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
“A recent meta-analysis of 17 RCTs found that SSRIs separate from placebo as early as 2 weeks and that majority of improvement occurs early on in the course of treatment [20].”
BackgroundInfluentialInvestigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
A closer look to neural pathways and psychopharmacology of obsessive compulsive disorder
Gargano, S. P., Santos, M. G., Taylor, S. M., & Pastis, I. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282246 · Cited by 18
Metadata
- Authors
- Serata, D., Kotzalidis, G. D., Rapinesi, C., Janiri, D., Di Pietro, S., Callovini, G., Piacentino, D., Gasperoni, C., Brugnoli, R., Ferri, V. R., Girardi, N., Tatarelli, R., Ferracuti, S., Angeletti, G., Girardi, P., & Del Casale, A.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2015-02-10
- Volume
- 30
- Issue
- 2
- Pages
- 70-84
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1945842134
- Cited by
- 30
- References
- 17
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.